Analgesic / Pain Killer
Central Nervous System Agent
Naproxen is a nonsteroidal anti-inflammatory drug. It works by reducing hormones that cause inflammation and pain in the body.
- Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.
- Rheumatoid arthritis, Osteoarthritis and ankylosing spondylitis: The dosage is two 375 mg or 500 mg tablets once daily, or one 750 mg tablet once daily.
- Management of Pain, PD, and Acute Tendinitis and Bursitis: The dosage is two 500 mg tablets once daily. For patients requiring greater analgesic benefit, two 750 mg tablets or three 500 mg tablets may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets
- For the treatment of Acute Gout: The dosage is two to three 500 mg tablets once daily on the first day, followed by two 500 mg tablets once daily, until the attack has subsided.
- Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.
- Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
- Heart Failure and Edema: Avoid use of NAPROXEN in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
- Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of NAPROXEN in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
- Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.
- Exacerbation of Asthma Related to Aspirin Sensitivity: NAPROXEN is contraindicated in patients with aspirin-sensitive. asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
- Serious Skin Reactions: Discontinue NAPROXEN at first appearance of skin rash or other signs of hypersensitivity.
- Premature Closure of Fetal Ductus Arteriosus: Avoid use in pregnant women starting at 30 weeks gestation.
- Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.
Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product.